In a major breakthrough development, DABUR India Limited, one of India’s leading Ayurvedic companies, has completed a large scale, multicentric, clinical study on their premium Ayurvedic healthcare product– DABUR Chyawanprash.
This clinical study evaluated the beneficial role of Dabur Chyawanprash as a prophylaxis remedy for COVID-19 infection. This study was conducted following applicable GCP guidelines, was approved by multiple Institutional Ethics Committees and was registered with Clinical Trials Registry of India which is a portal of ICMR. Subjects were enrolled in the study after taking an informed consent from all the study participants.
The findings of the study reveal that regular use of Dabur Chyawanprash reduced the risk of COVID-19 infection by up to 12 times in comparison to control group which was not consuming Chyawanprash. It was also noted that with regular usage of Dabur Chyawanprash, there was up to 6 times lesser severity of COVID 19 infections when compared to subjects in control group. The severity of COVID-19 was assessed as per
ordinal scale published by the WHO (World Health Organization) for COVID-19.